Nyrada Inc (NYR) - Total Liabilities
Based on the latest financial reports, Nyrada Inc (NYR) has total liabilities worth AU$548.97K AUD (≈ $388.43K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nyrada Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Nyrada Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Nyrada Inc to evaluate short-term liquidity relative to the company's equity base.
Nyrada Inc Competitors by Total Liabilities
The table below lists competitors of Nyrada Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scully Royalty Ltd
F:MB01
|
Germany | €127.77 Million |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩79.70 Billion |
|
Canterbury Park Holding Corporation
NASDAQ:CPHC
|
USA | $18.90 Million |
|
Questerre Energy Corporation
TO:QEC
|
Canada | CA$249.80 Million |
|
Columbus Acquisition Corp Ordinary Shares
NASDAQ:COLA
|
USA | $106.25K |
|
Jung Shing Wire Co Ltd
TW:1617
|
Taiwan | NT$1.14 Billion |
|
Gopeng Bhd
KLSE:2135
|
Malaysia | RM243.67 Million |
|
Chinese Gamer International
TWO:3083
|
Taiwan | NT$115.89 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Nyrada Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Nyrada Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nyrada Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nyrada Inc (2018–2025)
The table below shows the annual total liabilities of Nyrada Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.72 Million ≈ $1.22 Million |
+101.40% |
| 2024-06-30 | AU$855.63K ≈ $605.41K |
-5.59% |
| 2023-06-30 | AU$906.28K ≈ $641.25K |
+75.81% |
| 2022-06-30 | AU$515.48K ≈ $364.73K |
-22.53% |
| 2021-06-30 | AU$665.38K ≈ $470.80K |
-10.16% |
| 2020-06-30 | AU$740.67K ≈ $524.07K |
-87.85% |
| 2019-06-30 | AU$6.10 Million ≈ $4.31 Million |
+34.52% |
| 2018-06-30 | AU$4.53 Million ≈ $3.21 Million |
-- |
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more